NS5A-ISGylation via Lysine 26 Has a Critical Role for Efficient Propagation of Hepatitis C Virus Genotype 2a.
Lys residue
hepatitis C virus
viral propagation
Journal
The Kobe journal of medical sciences
ISSN: 1883-0498
Titre abrégé: Kobe J Med Sci
Pays: Japan
ID NLM: 0413531
Informations de publication
Date de publication:
30 Sep 2021
30 Sep 2021
Historique:
entrez:
19
11
2021
pubmed:
20
11
2021
medline:
24
12
2021
Statut:
epublish
Résumé
We previously reported that hepatitis C virus (HCV) NS5A (1b, Con1) protein accepts covalent ISG15 conjugation at specific lysine (Lys) residues (K44, K68, K166, K215 and K308), exhibiting proviral effects on HCV RNA replication. Here we investigated a role of NS5A-ISGylation via Lys residues in HCV propagation using HCV infectious clone. The alignment of amino acid sequences revealed that 5 Lys residues (K20, K26, K44, K139, and K166) of the 13 Lys residues within NS5A (genotype 2a, JFH1 strain) were conserved compared to those of HCV (genotype 1b, Con1 strain). The cell-based ISGylation assay revealed that the K26 residue in the amphipathic helix (AH) domain and the K139 residue in domain I of NS5A (2a, JFH1) had the potential to accept ISGylation. Use of the HCV replicon carrying luciferase gene revealed that the K26 residue but not K139 residue of NS5A (2a, JFH1) was important for HCV RNA replication. Furthermore, cell culture HCV revealed that the mutation with the K26 residue in combination with K139 or K166 on NS5A (2a, JFH1) resulted in complete abolishment of viral propagation, suggesting that the K26 residue collaborates with either the K139 residue or K166 residue for efficient HCV propagation. Taken together, these results suggest that HCV NS5A protein has the potential to accept ISGylation via specific Lys residues, involving efficient viral propagation in a genotype-specific manner.
Substances chimiques
Cytokines
0
RNA, Viral
0
Ubiquitins
0
Viral Nonstructural Proteins
0
ISG15 protein, human
60267-61-0
NS-5 protein, hepatitis C virus
EC 2.7.7.48
Lysine
K3Z4F929H6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E38-E47Références
Nature. 2005 May 19;435(7040):374-9
pubmed: 15902263
J Gen Virol. 2009 Jun;90(Pt 6):1329-1334
pubmed: 19264615
J Virol. 2020 Sep 29;94(20):
pubmed: 32727878
PLoS One. 2009 Aug 10;4(8):e6561
pubmed: 19668344
Ann Intern Med. 2017 May 2;166(9):637-648
pubmed: 28319996
Nature. 2010 May 6;465(7294):96-100
pubmed: 20410884
Gut. 2010 Aug;59(8):1111-9
pubmed: 20639253
Science. 2005 Jul 22;309(5734):623-6
pubmed: 15947137
J Virol. 2011 Jul;85(14):7460-4
pubmed: 21593166
Lancet. 2015 Mar 21;385(9973):1124-35
pubmed: 25687730
J Gen Virol. 2010 Feb;91(Pt 2):382-8
pubmed: 19846672
J Virol. 2006 Oct;80(20):10253-7
pubmed: 17005703
J Gen Virol. 2009 Dec;90(Pt 12):2929-2939
pubmed: 19656964
Protein Sci. 2014 Jun;23(6):723-34
pubmed: 24639329
J Gen Virol. 2013 May;94(Pt 5):1009-1018
pubmed: 23324467
Curr Top Microbiol Immunol. 2013;369:167-98
pubmed: 23463201
J Virol. 2003 May;77(10):6055-61
pubmed: 12719597
Biochem Biophys Res Commun. 2009 Apr 17;381(4):634-8
pubmed: 19249289
Virology. 2019 Sep;535:283-296
pubmed: 31369938
PLoS Pathog. 2008 Mar 28;4(3):e1000035
pubmed: 18369481
Gut. 2015 Nov;64(11):1824-33
pubmed: 26449729
Nat Rev Microbiol. 2018 Feb 12;16(3):125-142
pubmed: 29430005
Virology. 2015 May;479-480:418-33
pubmed: 25746936
Antimicrob Agents Chemother. 2012 Oct;56(10):5365-73
pubmed: 22869572
Antimicrob Agents Chemother. 2014 Sep;58(9):5386-94
pubmed: 24982066
J Interferon Cytokine Res. 2011 Jan;31(1):119-30
pubmed: 21190487
Nat Rev Microbiol. 2018 Jul;16(7):423-439
pubmed: 29769653
Nat Rev Microbiol. 2007 Jun;5(6):453-63
pubmed: 17487147
J Virol. 1997 Nov;71(11):8416-28
pubmed: 9343198
Microbiol Immunol. 2017 Jul;61(7):287-292
pubmed: 28543875
Nat Med. 2005 Jul;11(7):791-6
pubmed: 15951748
Hepatology. 2015 Jan;61(1):77-87
pubmed: 25069599
J Virol. 2009 May;83(9):4395-403
pubmed: 19244328
Antiviral Res. 2013 Dec;100(3):654-61
pubmed: 24416772